Movalis: instruction (action, contraindications to admission)

The drug "Movalis" (the instruction in detail describes its action) has anti-inflammatory, antipyretic and analgesic properties. Active ingredient in it is meloxicam - a substance belonging to the class of non-steroidal anti-inflammatory drugs. In addition to the "Movalis", meloxicam is a part of several drugs of a similar effect with the trade names "Matarin", "Amelotex", "Meloflam", etc.

Meloksikam is used in the treatment of arthritis, with feverish conditions and inflammatory processes of various nature. It significantly alleviates the patient's condition with osteoarthritis, rheumatoid arthritis, degenerative joint diseases, as well as with Bechterew's disease (ankylosing spondylitis), a chronic inflammatory disease that primarily affects the spine.

"Movalis", the instruction to which contains a list of recommendations for the use of the drug, is available in the form of tablets, rectal suppositories (suppositories) and solution for injections in ampoules. Each tablet, except 7.5 or 15 mg meloxicam, contains sodium citrate, magnesium stearate, povidone, lactose, etc. The composition of the candles "Movalis", in addition to meloxicam (7.5 or 15 mg), includes suppository mass and others Excipients. One ampoule of "Movalisa" (1.5 ml) contains 15 mg of meloxicam in the form of a solution for injections - a transparent liquid of greenish color.

The drug is well absorbed after administration or rectally. The maximum possible level of meloxicam in the blood plasma in this case is reached within five to six hours, after injections - about an hour later. Its concentration in the synovial fluid is usually two times lower than in plasma. When administered intramuscularly, it is absorbed 100%. The half-life period of meloxicam is twenty hours after admission.

Medicines containing meloxicam effectively combat pain syndrome and inflammatory processes in the joints. However, the use of the drug "Movalis" (the instruction draws attention to this) can have quite serious side effects, ranging from pruritus and urticaria, digestive disorders and abdominal pains to attacks of bronchial asthma and angioedema. Fortunately, these dangerous complications are very rare.

Other side effects of Movalis are possible: increased blood pressure, increased heart rate, the appearance of edema. There may also be problems with vision (blurry images), conjunctivitis may develop, and the parameters of the clinical blood test may change. The question of the expediency of using the drug "Movalis", the instruction to which describes all possible negative consequences of its use, is decided in each case by the attending physician. It should be noted, however, that side effects after taking this medication are noted much less frequently and are faster than after other drugs of similar effect.

The recommended dose of "Movalis" is 7.5 mg per day. In case of an exacerbation of Bechterew's disease and rheumatoid arthritis, a dose of 15 mg / day is first used, and when a noticeable effect is achieved, it is reduced by half. "Movalis" (injections) can not be administered to patients in parallel with anticoagulants. The drug in any dosage form is contraindicated in pregnant women, nursing mothers and children under 15 years old, as well as those who have already experienced allergic reactions to other NSAIDs - in particular, to acetylsalicylic acid. The instructions attached to the "Movalis" preparation are recommended to do slowly, but to inject the solution deeply. Tablets must also be taken with food, washed down with water. It should be remembered that the "Movalis" solution is not intended for intravenous administration.